Refractory pouchitis in PSC: anti-TNF or diversion

What is known

• For PSC-associated CARP, budesonide or oral vancomycin is described first-line, with step-up to biologics including anti-TNF, vedolizumab, and ustekinumab. ¹
• One review recommends reserving anti-TNF for patients who fail vedolizumab and ustekinumab. ¹
• Surgery (end ileostomy with or without pouch excision) is described as a last resort after failure of all medical therapy, with high complication rates and trade-offs between pouch excision and diversion. ¹
• A case reports successful vedolizumab treatment of anti-TNF-refractory chronic pouchitis with concomitant PSC, indicating some patients do not respond to anti-TNF. ²

What is unknown / caveats

• No head-to-head anti-TNF vs fecal diversion data
• PSC-pouchitis treatment-response data are limited and largely from small cohorts/case reports
• The excerpts do not establish comparative efficacy or outcomes between anti-TNF and fecal diversion in this population.

References

1. Ardalan ZS, Sparrow MP. A Personalized Approach to Managing Patients With an Ileal Pouch-Anal Anastomosis. Front Med (Lausanne). 2019;6:337. PMID: 32064264.

2. Coletta M, Paroni M, Caprioli F. Successful Treatment With Vedolizumab in a Patient With Chronic Refractory Pouchitis and Primary Sclerosing Cholangitis. J Crohns Colitis. 2017;11:1507-1508. PMID: 29106505.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.